Monoclonal antibody that binds human notch2 and notch3

Patent metadata

Field	Value
Publication number	US-8980260-B2
Application number	US-201313826432-A
Country	US
Kind code	B2
Filing date	Mar 14, 2013
Priority date	Jul 8, 2008
Publication date	Mar 17, 2015
Grant date	Mar 17, 2015

Abstract

The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

First claim

What is claimed is:

1. An isolated monoclonal antibody that specifically binds epidermal growth factor (EGF) repeat 10 of human NOTCH2 and EGF repeat 9 of human NOTCH3.

2. The antibody of claim 1 , which binds at least part of the sequence HKGAL (SEQ ID NO:28) within EGF repeat 10 of human NOTCH2.

3. The antibody of claim 2 , which binds at least part of the sequence HEDAI (SEQ ID NO:29) within EGF repeat 9 of human NOTCH3.

4. The antibody of claim 1 , which binds at least part of the sequence HEDAI (SEQ ID NO:29) within EGF repeat 9 of human NOTCH3.

5. The antibody of claim 1 , which binds human NOTCH2 with a K D of about 1 nM or less.

6. The antibody of claim 5 , which binds human NOTCH3 with a K D of about 1 nM or less.

7. The antibody of claim 1 , which binds human NOTCH3 with a K D of about 1 nM or less.

8. The antibody of claim 1 , which is a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, a bispecific antibody, a monospecific antibody, an antibody fragment, an IgG1 antibody, or an IgG2 antibody.

9. The antibody of claim 8 , which is a human antibody.

10. The antibody of claim 8 , which is a humanized antibody.

11. The antibody of claim 8 , which is an IgG1 antibody.

12. The antibody of claim 8 , which is an IgG2 antibody.

13. The antibody of claim 1 , which is an antagonist of human NOTCH2 and/or human NOTCH3.

14. The antibody of claim 1 , which inhibits binding of a ligand to human NOTCH2 and/or human NOTCH3.

15. The antibody of claim 1 , which inhibits human NOTCH2 and/or human NOTCH3 signaling.

16. The antibody of claim 1 , which inhibits tumor growth.

Assignees

• Oncomed Pharm Inc
• Oncomed Pharm Inc

Inventors

• Gurney Austin L
• Hoey Timothy Charles
• Van Der Horst Edward Thein Htun
• Sato Aaron Ken
• Liu Yuan Ching
• Bruhns Maureen Fitch
• Lewicki John A

Classifications

• A61P35/04

  specific for metastasis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/337 Primary

  having four-membered rings, e.g. taxol · CPC title